All Forums  Abstract Submissions  Biacore S51 for drug discovery

Note: You must be registered in order to post a reply.
To register, click here. Registration is FREE!

Screensize: 640 x 480 800 x 600 1024 x 768 1280 x 1024 UserName: Password: Format: Andale Mono Arial Arial Black Book Antiqua Century Gothic Comic Sans MS Courier New Georgia Impact Tahoma Times New Roman Trebuchet MS Script MT Bold Stencil Verdana Lucida Console   1 2 3 4 5 6   Black Red Yellow Pink Green Orange Purple Blue Beige Brown Teal Navy Maroon LimeGreen Message: * HTML is OFF * Forum Code is ON [quote] High through put screening (HTS) is not the bottle neck in drug discovery, rather deciding which hit is the best lead to optimize and take into clinical trials is the most critical. The Biacore S51 is a new automated biosensor specifically optimized for direct binding assays with small molecules in non-aqueous buffers (e.g. DMSO). This platform is ideal for hit confirmation, characterization and lead optimization including secondary screening (specificity, relative ranking), compound characterization (affinity, kinetics), early ADME (lipid and serum protein binding), and kinetic based QSAR analysis. Unpromising hits can be identified and discarded earlier in the drug discovery process, saving millions of dollars in development costs. Compounds taken to clinical trials have a higher chance of success. For more information see this link http://www.biacore.com/products/systemsandsoftware/s51/bcs51.lasso?goback=1, or contact Evan Behre, Sales Account Scientist, Biacore, Inc. ebehre@biacoreinc.com Edited by - ebehre on 09/25/2002 14:29:34 [/quote]   Mode: Help  Prompt  Basic  Check here to include your profile signature.